Management of Stage 2-3a CKD in a 53-Year-Old Male
This patient with an eGFR of 66 mL/min/1.73 m² has Stage 2-3a chronic kidney disease and requires comprehensive evaluation of albuminuria status, blood pressure control, and consideration of kidney-protective therapies based on the 2024 KDIGO guidelines.
Initial Diagnostic Workup
The first critical step is determining albuminuria status, as this fundamentally changes management strategy 1:
- Obtain urine albumin-to-creatinine ratio (ACR) to classify CKD stage (A1: <30 mg/g, A2: 30-300 mg/g, A3: >300 mg/g) 1
- Assess for diabetes status and cardiovascular comorbidities 1, 2
- Check serum potassium before initiating any kidney-protective medications 1
- Evaluate blood pressure with target <130/80 mmHg for all CKD patients 3
Pharmacologic Management Algorithm
If ACR ≥200 mg/g OR Heart Failure Present:
Start SGLT2 inhibitor immediately (1A recommendation) - this is the strongest evidence-based intervention for reducing CKD progression, cardiovascular events, and mortality 1. The 2024 KDIGO guidelines provide a 1A recommendation for SGLT2i in adults with CKD and eGFR ≥20 mL/min/1.73 m² when ACR ≥200 mg/g or heart failure exists 1.
If ACR 30-200 mg/g (A2):
- With diabetes: Start both RAS inhibitor (ACEi or ARB) AND SGLT2 inhibitor 1
- Without diabetes: Start RAS inhibitor (ACEi or ARB) at maximum tolerated dose (2C recommendation) 1
- Consider adding SGLT2 inhibitor if eGFR 20-45 mL/min/1.73 m² (2B recommendation) 1
If ACR <30 mg/g (A1):
- Consider RAS inhibitor only for specific indications like hypertension or heart failure with reduced ejection fraction 1
- SGLT2 inhibitor has weaker evidence in this group but may still be considered (2B recommendation if eGFR 20-45) 1
Monitoring After Medication Initiation
Check BP, serum creatinine, and potassium within 2-4 weeks of starting or increasing dose of RAS inhibitors 1:
- Continue RASi unless creatinine rises >30% within 4 weeks 1
- Manage hyperkalemia with potassium-lowering measures rather than stopping RASi when possible 1
- SGLT2i does not require altered monitoring frequency and initial eGFR dip is expected and not an indication to stop 1
Additional Considerations for Diabetes Patients
If this patient has type 2 diabetes with persistent albuminuria despite maximum RASi therapy:
- Add nonsteroidal MRA (finerenone) if eGFR >25 mL/min/1.73 m², normal potassium, and ACR >30 mg/g (2A recommendation) 1
- Dose finerenone 10 mg daily for eGFR 25-59 mL/min/1.73 m² 1
- Monitor potassium at 1 month, then every 4 months 1
Critical Pitfalls to Avoid
- Do not stop RASi when eGFR falls below 30 mL/min/1.73 m² - continue unless specific contraindications develop 1
- Do not discontinue SGLT2i for initial eGFR decrease - this is expected and reversible 1
- Do not use serum creatinine alone to assess kidney function in older adults or those with low muscle mass 2, 4
- Avoid nephrotoxins including NSAIDs and adjust medication dosing appropriately for renal function 2
Cardiovascular Risk Reduction
Initiate statin therapy for cardiovascular risk reduction, as cardiovascular death risk exceeds ESRD risk in CKD patients 2, 3:
- Target BP <130/80 mmHg with sodium restriction to <2 grams daily 3
- Address modifiable risk factors including weight loss if BMI >25 kg/m² 3
Monitoring for CKD Complications
At this eGFR level, begin monitoring for:
- Hyperkalemia, metabolic acidosis (especially if on RASi) 2
- Anemia screening if eGFR continues to decline toward <45 mL/min/1.73 m² 5
- Vitamin D and parathyroid hormone as eGFR approaches 30-45 mL/min/1.73 m² 2
Nephrology Referral Criteria
Refer to nephrology if 2:
- eGFR <30 mL/min/1.73 m²
- ACR ≥300 mg/g
- Rapid eGFR decline (>5 mL/min/1.73 m² per year)
- Unclear etiology of kidney disease